Journal: Cell chemical biology

Article Title: Stable and potent selenomab-drug conjugates

doi: 10.1016/j.chembiol.2017.02.012

Figure Lengend Snippet: Human multiple myeloma cell line U266-ffluc was i.v. (tail vein) injected into NSG mice. After 4 weeks, the mice were randomized into 3 groups comprising 8–9 mice each and treated with i.v. (tail vein) injections of 3 mg/kg of the ADC, the unconjugated antibody, and vehicle alone. (A) Human lambda light chain concentrations correlating with tumor burden were determined by ELISA at the indicated time points and plotted as mean ± SD values. The p value (t-test) compares the ADC group to the unconjugated antibody group. (B) Kaplan-Meier survival curve. The p value (log-rank test) compares the ADC group to the unconjugated antibody group. See also Figure S3 and Table S3.

Article Snippet: Human: U266 , ATCC , Cat#TIB-196.

Techniques: Injection, Enzyme-linked Immunosorbent Assay

Journal: Cell chemical biology

Article Title: Stable and potent selenomab-drug conjugates

doi: 10.1016/j.chembiol.2017.02.012

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Human: U266 , ATCC , Cat#TIB-196.

Techniques: Virus, Recombinant, Marker, Conjugation Assay, Proliferation Assay, Enzyme-linked Immunosorbent Assay, Quantitation Assay, Software

Journal: Cells

Article Title: Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

doi: 10.3390/cells13100879

Figure Lengend Snippet: Materials used in this study.

Article Snippet: Human multiple myeloma cell lines (HMCL), i.e., MM1S, U266, AMO, AMO-TP53, RPMI 8226, INA-6, OPM-2, LP-1, KMS-11BM, and KMS-11, were purchased from DSMZ (Braunschweig, Germany).

Techniques: Conjugation Assay, Staining, Purification, Software

Journal: Cells

Article Title: Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

doi: 10.3390/cells13100879

Figure Lengend Snippet: Characterization of SAR442257 potency in human multiple myeloma cell lines (HMCLs): ( a ) SAR442257 geometry; ( b ) correlation of target expression (in molecules of equivalent soluble fluorochrome (MESF)) of CD38 and CD28 on 10 HMCL. We measured CD38 and CD28 target expression and found a linear relationship with Pearson’s r = 0.7, p = 0.03. ( c – e ) Cellular avidity ranks as a percentage of TCs bound to MM cells by indicated TC engagers (triple knockout (KO), SAR442257, CD38-CD3-antibody (AB), CD28-CD3-AB, CD38 AB) for U266 ( d ) and MM1S ( e ). ( f – h ) Dose response curves of SAR442257 or triple KO control in ( g ) U266 and ( h ) MM1S with healthy donor TCs (E:T = 10:1). (Significance was determined using TTEST, * p < 0.05, *** p < 0.001).

Article Snippet: Human multiple myeloma cell lines (HMCL), i.e., MM1S, U266, AMO, AMO-TP53, RPMI 8226, INA-6, OPM-2, LP-1, KMS-11BM, and KMS-11, were purchased from DSMZ (Braunschweig, Germany).

Techniques: Expressing, Triple Knockout, Control

Journal: Cells

Article Title: Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

doi: 10.3390/cells13100879

Figure Lengend Snippet: Presence of TGF-β in co-culture reduces TCE efficiency. ( a ) Sketch of the experimental setup ( b , c ) After a 24-hour culture in TGF-β-supplemented medium, healthy donor TCs are subsequently introduced into a co-culture with ( b ) U266 and ( c ) MM1S. TGF-β significantly reduced the drug potency of SAR442257. ( d – f ) Primary T cells were isolated from patient samples, and MM cells (MMCs) were co-cultured in the presence of the natural bone marrow microenvironment (BMME, CD138-CD3 fraction). Vactoserib, SAR442257, or a combination of vactoserib and SAR442257 were then added to the co-culture system. Vactoserib-SAR442257 combinations overcome TGF-β-induced T cell exhaustion. SAR442257 induced significantly higher MM cell killing in the presence of vactoserib in ( e ) bispecific antibodies for TC engagement and ( f ) anti-CD38-refractory samples. Viability was measured after 24 h of co-culture using FACS. All measurements were carried out in duplicates (significance was determined using TTEST, * p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: Human multiple myeloma cell lines (HMCL), i.e., MM1S, U266, AMO, AMO-TP53, RPMI 8226, INA-6, OPM-2, LP-1, KMS-11BM, and KMS-11, were purchased from DSMZ (Braunschweig, Germany).

Techniques: Co-Culture Assay, Isolation, Cell Culture

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Identification of constructed TCF4−/+ U266 and MMSA−1−/+ U266 stable cell lines and MMSA-1 mRNA and protein levels in TCF4−/+ U266 cells 1: U266 cells; 2: TCF4− U266-NC; 3. TCF4− U266 cells; 4: TCF4+ U266-NC; 5. TCF4+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Construct, Stable Transfection

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Dual-Luciferase Report Assay results in different U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Luciferase

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1 and RAS co-localization and interaction in U266 cells 1: U266 cells; 2: MMSA−1− U266-NC; 3. MMSA−1− U266 cells; 4: MMSA−1+ U266-NC; 5. MMSA−1+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: RAS downstream related molecule expressions in different U266 cells 1: U266; 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4: MMSA−1+ U266-NC; 5. MMSA−1 + U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1’s effect on U266 cells proliferation, migration and apoptosis A showed cloning formation assay result; B showed transwell assay result; C showed apoptosis related proteins expression and D showed mitochondrial apoptosis in different U266 cells. 1: U266; 2: U266 + CCCP-1; 3. MMSA−1− U266-NC; 4. MMSA−1− U266-NC + CCCP-1; 5. MMSA−1− U266; 6: MMSA−1− U266 + CCCP-1; 7. MMSA−1+ U266-NC; 8. MMSA−1+ U266-NC + CCCP-1; 9. MMSA−1 + U266; 10. MMSA−1 + U266 + CCCP-1

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Migration, Cloning, Tube Formation Assay, Transwell Assay, Expressing

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Adhesion molecules and angiogenesis factors levels in different U266 cells A showed qRT-PCR result and B showed Western Blot result of adhesion molecules; C showed angiogenesis factors levels. 1: U266 cells, 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4. MMSA−1+ U266-NC; 5. MMSA−1+ U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Quantitative RT-PCR, Western Blot